Imprimis Pharmaceuticals Names Seasoned Ophthalmology Executive John Saharek As Vice-President Of Commercialization For Its Ophthalmology Division

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced the hiring of John Saharek to serve as Vice-President of Commercialization for Ophthalmology.

In his role leading commercialization activities for Imprimis's two lead ophthalmic compounded formulations, Saharek will be chiefly responsible for the "Go Dropless" marketing campaign and related outreach to leading ophthalmologists in the US and abroad. Imprimis's first compounded formulation is a combination of two or more of Triamcinolone + Moxifloxicin + Vancomycin as an injectable solution. What makes Imprimis's patent-pending formulation unique is that these formulations are in an injectable solution that can be administered during certain eye surgeries. No mixing, shaking or adding anything simply draw and inject. Imprimis's second compounded drug formulation is a patent-pending lyophilized Epinephrine + Lidocaine or Phenylephrine + Lidocaine. Imprimis believes these formulations, which are easily reconstituted prior to injection, will offer eye surgeons a stable and reliable source of known mydriatic agents. In an effort to create awareness about these formulations, Imprimis will soon debut its "Go Dropless" campaign which will encourage ophthalmologists to consider reducing dependence on post-op eye drops, freeing their patients from the expense and inconvenience of eye drops and to simplify their lives with less pharmacy and more control.

"John is an experienced ophthalmology industry leader with a 25 year track record of delivering results to a range of leading companies," said Mark L. Baum, Chief Executive Officer of Imprimis. "John will complete the build out of our commercialization team and will drive our market awareness activities for our innovative ophthalmology solutions. We are pleased to continue to add new, high-caliber individuals like John to the Imprimis team as we focus on execution and delivering results for our shareholders."

"I am excited to join the Imprimis team, to be able to lead our commercialization efforts at this exciting time," said Saharek. "So many innovative treatments are being developed for patients through the clinical interaction between pharmacists and physicians. It is an honor to help Imprimis take its unique patent-pending innovations to a broader set of patients across the country. Patients deserve and expect personalized medicine. We can deliver that care in a way that serves our patients, our physician and pharmacist partners, and our shareholders."

Saharek most recently served as Head of U.S. Marketing and Strategy for ThromboGenics Inc., developing the commercialization strategy for its ophthalmology business. Prior to that he was Vice President, Business Development at SurModics Inc., after spending six years managing sales and marketing for cataract and vitreoretinal surgical and drug products for Bausch & Lomb. Saharek began his career in marketing at Boehringer Mannheim.

ABOUT IMPRIMIS PHARMACEUTICALS

Imprimis Pharmaceuticals, Inc. (IMMY) is a pharmaceutical company focused on the commercial development of novel drug formulations and proprietary drug delivery vehicles. Imprimis believes in the power of the clinical interaction of one patient, one physician and one pharmacist to build novel therapeutic approaches that have broad market appeal. Drug formulations created by pharmacists and physicians for a specific patient's use are investigated using through a proprietary and rigorous evaluation process, the Asset Review Methodology (ARM), in order to assess potential for commercialization. Following this evaluation process, including clinical development, the company may choose to pursue FDA approval through the FDA's Section 505(b)(2) development pathway, or selectively make its treatment options available to the market through pharmacy compounding. In addition, Imprimis expects to seek partnerships with wholesalers in order to make its drug delivery technologies available to compounding pharmacies across North America. The company's current focus is in the Ophthalmology, Wound Management, Urology and Pain therapeutic areas.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Imprimis' results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis' ability to acquire, develop, commercialize and market new formulations and technologies, enter into strategic alliances and transactions, including arrangements with pharmacies, physicians and healthcare organizations, commercialize its formulations and technologies, obtain intellectual property protection for its assets, accurately estimate its expenses and cash burn, and raise additional funds, as well as the success of additional research and development activities related to its formulations and technologies, the projected size of the potential market for its technologies and formulations, unexpected new data, safety and technical issues, regulatory and market developments impacting compounding pharmacies and the pharmaceutical industry, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

For Media Inquiries:

Contact: Arielle Sklar or Robert Zito
212-403-6812

For Investor Inquiries:

BPC Financial Marketing
Contact: John Baldissera
800-368-1217

SOURCE Imprimis Pharmaceuticals